232 related articles for article (PubMed ID: 34199461)
1. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology.
Rousset-Rouviere S; Rochigneux P; Chrétien AS; Fattori S; Gorvel L; Provansal M; Lambaudie E; Olive D; Sabatier R
Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34199461
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis.
Johnson RL; Ganesan S; Thangavelu A; Theophilou G; de Jong D; Hutson R; Nugent D; Broadhead T; Laios A; Cummings M; Orsi NM
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760602
[TBL] [Abstract][Full Text] [Related]
3. Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab.
El-Ghazzi N; Durando X; Giro A; Herrmann T
Onco Targets Ther; 2023; 16():359-369. PubMed ID: 37288137
[TBL] [Abstract][Full Text] [Related]
4. High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer.
Guo J; Tang B; Fu J; Zhu X; Xie W; Wang N; Ding Z; Song Z; Yang Y; Xu G; Xiao X
Cell Oncol (Dordr); 2024 Apr; 47(2):573-585. PubMed ID: 37847338
[TBL] [Abstract][Full Text] [Related]
5. The Revolution of Immunotherapy in Gynecological Cancers: The Lazarus Effect in Endometrial Cancer.
Ducceschi M; Polignano M; Bini M; Lopez S; Conca E; Tamborini E; Perrone F; Carlo Stella G; Petrella MC; Carciotto R; Artioli G; Maffeis V; Sartor L; Raspagliesi F; Mantiero M
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685607
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.
Mittica G; Ghisoni E; Giannone G; Aglietta M; Genta S; Valabrega G
Oncotarget; 2017 Oct; 8(52):90532-90544. PubMed ID: 29163851
[TBL] [Abstract][Full Text] [Related]
7. Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens.
Richardson M; Chase DM
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):1-8. PubMed ID: 37792525
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations.
Tsai AK; Kagalwalla S; Langer J; Le-Kumar T; Le-Kumar V; Antonarakis ES
Expert Opin Biol Ther; 2024; 24(1-2):51-62. PubMed ID: 38284349
[TBL] [Abstract][Full Text] [Related]
9. Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Loizzi V; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G
Front Oncol; 2023; 13():1247291. PubMed ID: 37781174
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer.
Wan X; Huang J; Huang L; Wang Y; Fu Y; Jin X; Huang Z; Xiong J
Discov Oncol; 2024 May; 15(1):168. PubMed ID: 38750182
[TBL] [Abstract][Full Text] [Related]
11. Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status.
Sawada K; Nakayama K; Razia S; Yamashita H; Ishibashi T; Ishikawa M; Kanno K; Sato S; Nakayama S; Otsuki Y; Kyo S
Healthcare (Basel); 2023 Apr; 11(8):. PubMed ID: 37107907
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.
Pacholczak-Madej R; Bartoletti M; Musacchio L; Püsküllüoglu M; Blecharz P; Lorusso D
Expert Rev Anticancer Ther; 2024 Jun; ():1-13. PubMed ID: 38863432
[TBL] [Abstract][Full Text] [Related]
13. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
Rodrigues M; Eberst L; Follana P; Gauthier L; Jacquemin V; Tessier C; El Mouaddin N; Boudier P; Fiteni F; Angeli E; Roche S; Delanoy N; Sabatier R; Flippot R; de la Motte Rouge T
Bull Cancer; 2023 Oct; 110(10):1041-1050. PubMed ID: 37659907
[TBL] [Abstract][Full Text] [Related]
14. Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors.
Lainé A; Gonzalez-Lopez AM; Hasan U; Ohkuma R; Ray-Coquard I
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046702
[TBL] [Abstract][Full Text] [Related]
15. Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm.
Goulden S; Shen Q; Coleman RL; Mathews C; Hunger M; Pahwa A; Schade R
J Health Econ Outcomes Res; 2023; 10(2):53-61. PubMed ID: 37701519
[No Abstract] [Full Text] [Related]
16. Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series.
Rose PG; Feldman M; Podzielinski I; Petty AP; Vargas R
Gynecol Oncol Rep; 2023 Dec; 50():101303. PubMed ID: 38054201
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States.
Coleman RL; Garside J; Hurteau J; Nguyen J; Kobayashi M
J Health Econ Outcomes Res; 2023; 10(2):82-90. PubMed ID: 37905183
[No Abstract] [Full Text] [Related]
18. Long-term disease-free survival with chemotherapy and pembrolizumab in a patient with unmeasurable, advanced stage dedifferentiated endometrial carcinoma.
Davis JM; Rushton T; Nsiah F; Stone RL; Beavis AL; Gaillard SL; Dobi A; Fader AN
Gynecol Oncol Rep; 2024 Jun; 53():101380. PubMed ID: 38601712
[TBL] [Abstract][Full Text] [Related]
19. Dostarlimab for the Treatment of Endometrial Cancer: A Review.
Stewart CE; Chase D
Touch Rev Oncol Haematol; 2024; 20(1):9-11. PubMed ID: 38855381
[TBL] [Abstract][Full Text] [Related]
20. A case series on the efficacy and safety of a PD-1 inhibitor combined with antiangiogenic agents in the treatment of recurrent MSI-H endometrial cancer.
Song H; Du Z; Xiao H; Tian J; Wang K; Liu W
Gland Surg; 2023 Aug; 12(8):1075-1081. PubMed ID: 37701298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
